Biopharmaceutical production in mammalian cell culture has expanded steadily since its emergence in the global pharmaceutical market. The overall product profile has shifted markedly over time thanks to scientific advances in antibody discovery, development, and manufacturing. To meet market demands, biomanufacturers have increased their capacity significantly over the past two decades. Product-sponsor companies traditionally have held the most such capacity. However, contract manufacturing organizations (CMOs) are projected to increase their control of capacity.

BioProcess Insider teamed with CPHI Milan, the world’s largest pharma event, to bring you a detailed dive into current biomanufacturing capacity trends, specifically for mammalian-cell production. In this eBook, Dawn Ecker (managing director of bioTRAK database services for BioProcess Technology Group, BDO USA) compares current and historic capabilities in the sector. And she predicts how geographical and company-based distribution of capacity will evolve going forward.

Register or Login and hit Download Now to get the full eBook.